|Dr. David H. Mack||Co-Founder, CEO, Pres & Director||770.33k||N/A||1962|
|Dr. Arnold J. Levine Ph.D.||Co-Founder, Independent Director & Member of Scientific Advisory Board||110k||N/A||1940|
|Mr. Winston Kung||COO & CFO||608.93k||N/A||1976|
|Dr. Leila Alland||Chief Medical Officer||629.67k||N/A||1963|
|Dr. Thomas E. Shenk Ph.D.||Co-Founder & Member of Scientific Advisory Board||N/A||N/A||1947|
|Mr. Robert Ticktin||Gen. Counsel & Company Sec.||N/A||N/A||1962|
|Dr. Deepika Jalota Pharm.D.||Chief Regulatory & Quality Assurance Officer||N/A||N/A||1977|
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores p53 function. It is also developing p53 R273H mutation and other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
PMV Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 1, 2021 is 10. The pillar scores are Audit: 6; Board: 10; Shareholder Rights: 8; Compensation: 9.